Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (NY: ANRO ) 10.63 +0.67 (+6.73%) Official Closing Price Updated: 7:00 PM EDT, Jun 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 114,967 Open 10.08 Bid (Size) 10.30 (1) Ask (Size) 20.00 (1) Prev. Close 9.960 Today's Range 10.01 - 10.88 52wk Range 9.400 - 24.00 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Alto Neuroscience Initiates Phase 2 Study of ALTO-101, a Novel PDE4 Inhibitor, in Cognitive Impairment Associated with Schizophrenia June 20, 2024 From Alto Neuroscience, Inc. Via Business Wire Amit Etkin, M.D., Ph.D., Founder and CEO of Alto Neuroscience, Named an EY Entrepreneur Of The Year® 2024 Bay Area Award Winner June 18, 2024 From Alto Neuroscience, Inc. Via Business Wire Performance YTD -48.65% -48.65% 1 Month -13.44% -13.44% 3 Month -30.75% -30.75% 6 Month -48.65% -48.65% 1 Year -48.65% -48.65% More News Read More Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On June 10, 2024 Via InvestorPlace Alto Neuroscience to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience Appoints Michael Hanley as Chief Operating Officer May 21, 2024 From Alto Neuroscience, Inc. Via Business Wire ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024 May 14, 2024 Via InvestorPlace Alto Neuroscience Reports First Quarter 2024 Financial Results and Recent Business Highlights May 14, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience Announces Data Presentations Highlighting Late-Stage Clinical Pipeline and Robust Platform at Upcoming Scientific Conferences May 09, 2024 From Alto Neuroscience, Inc. Via Business Wire Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape April 23, 2024 Via Benzinga Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia April 23, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder April 03, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights March 21, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors March 11, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience to Participate in Upcoming Investor Conferences March 07, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Alto Neuroscience, Inc. Via Business Wire Alto Neuroscience Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares February 06, 2024 From Alto Neuroscience, Inc. Via Business Wire Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday February 05, 2024 Via InvestorPlace Maker Of Wilson Tennis Rackets Raises $1.37 Billion In Discounted IPO February 04, 2024 Via Talk Markets Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
